Charcot neuropathy is a common complication resulting from poorly controlled diabetes and peripheral neuropathy leading to the collapse, and ultimately the breakdown, of the midfoot. Mechanically, it is likely that a compromised arch support in this, or any other patient group that experiences foot flattening, would be associated with slippage at the distal and proximal interface regions of the plantar surface of the foot and the adjacent support surface. This slippage, although difficult to quantify with standard motion capture systems used in a gait laboratory, could potentially be assessed with systems for monitoring interface shear stresses. However, before investing in such systems, a correlation between arch flattening and interface shear stresses needs to be verified.
For this purpose, a sagittal plane model of a foot was developed using a multi-body dynamics package (MSC Adams). This model mimicked a subject swaying back and forth, and was constructed to show the dependence of interface stresses on altered arch support.
The model's predictions matched typical FootSTEPS data lengthening of the arch of 1-2mm, sway oscillations of 0.22-0.33s and frictional force differences (calcaneus relative to forefoot) of 60N. Of clinical relevance, when the stiffness of the plantar spring (representing aponeurosis and intrinsic muscles) was reduced by 10%, the frictional force difference increased by about 6.5%.
The clinical implications of this study are that, while arch lengthening of less than 2mm might be difficult to measure reliably in a gait lab, using shear sensors under the forefoot and hindfoot should allow arch support to be assessed in a repeatable manner.
The clinical implications of this study are that, while arch lengthening of less than 2 mm might be difficult to measure reliably in a gait lab, using shear sensors under the forefoot and hindfoot should allow arch support to be assessed in a repeatable manner.
This study examined the association between index component score levels of the Dietary Approaches to Stop Hypertension (DASH) density-based index and the Healthy Eating Index-2015 (HEI-2015) for protein foods and a high-sensitivity C-reactive protein (hs-CRP) level in US adults with diabetes status.
This cross-sectional study used data from adult participants (≥20 y) in the National Health and Nutrition Examination Survey 2005-2010 (n=12070) to obtain hs-CRP levels and index scores in US adults. Odds ratios (OR) of having an elevated hs-CRP (>3.0 mg/L) by score levels of protein food components (low <80% versus high ≥80% of the maximum score) were acquired using survey multivariable logistic regression analysis.
After adjusting for age group, sex, race/ethnicity, and other potential confounders, participants with a low score were more likely to have an elevated hs-CRP level than those with a high score (DASH plant proteins and HEI-2015 seafood and plant proteins P < 0.001). Adults with diabetered to establish ideal density-based amounts or proportions of protein food subgroups.
The influence of living alone on multiple food and nutrition behaviors across a range of ages and genders has not been sufficiently investigated. Moreover, to our knowledge, no studies have described both dietary status and medical examination findings in persons living alone. Among individuals who attended a health checkup in a rural town in Japan, we investigated dietary habits and medical examination findings in persons living alone and those living with one or more other persons.
The participants in this investigation were 501 community-dwelling individuals aged 40 to 91 y (mean, 63.8 ± 9.9 y). Thirty-four (16.4%) of the 207 men and 45 (15.3%) of the 294 women lived alone. Dietary intake frequency of 28 types of foods and drinks, including various vegetables, fruits, meat, seafood, and dairy products, was investigated based on responses to a self-completed questionnaire. During the physical examination, body weight, body mass index, body fat percentage, and blood pressure (systolic and diastolic) weret also with an unfavorable trend in some of the medical examination findings.
Pumpkin and its seeds are increasingly consumed by children for their potential health benefits. Each day, approximately 30% of teenagers consume nuts and seeds, including pumpkin seeds. However, there is some evidence that pumpkin seeds may exert allergenic effects and induce severe life-threatening anaphylaxis. Allergy to melon, cucumber, and zucchini, which belong to the same Cucurbitaceae family as pumpkin, are well known, opposite to pumpkin allergy. Few descriptions of allergic reactions associated with pumpkin have been published, especially in children. To date, three cases of pumpkin pulp and two seed cases have been reported among children. Our case report describes a case of pumpkin seed anaphylaxis in a child with good tolerance of pulp.
In the present study, a 2-y-old child experienced anaphylaxis, presenting with generalized urticaria, swollen lips, and increasing dyspnea after consuming pumpkin seeds.
The patient's history showed that, although the child had been receiving an elimination s and nuts.
METHODS RESULTS CONCLUSION.
METHODS RESULTS CONCLUSION.
Effective therapies are lacking for recurrent, metastatic adenoid cystic carcinoma (R/M ACC) and preclinical models suggest retinoic acid agonists inhibit ACC growth. https://www.selleckchem.com/products/AZD1152-HQPA.html This phase II trial evaluated all-trans retinoic acid (ATRA) as a novel therapy for ACC.
Patients with R/M ACC (any site) with clinical and/or radiographic progression ≤12months prior to study entry were eligible. Cohort 1 (CH1) received ATRA 45mg/m
split oral daily dosing on days 1-14 of a 28-day cycle; Cohort 2 (CH2) received the same dosing continuously. Primary endpoint was best overall response rate (CR+PR) (RECIST v1.1). Secondary endpoints safety and progression-free survival (PFS). Exploratory analyses ATRA impact on MYB expression and genomic predictors of response.
Eighteen patients enrolled. There were no responses, but 61% (11/18) had stable disease (SD) and 28% (5/18) progression as best response; 11% (2/18) unevaluable. Median duration of stability 3.7months (95%CI, 1.9-3.9). One patient (CH1) remains on drug with SD approaching 1year.